Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Assessment of Vanzacaftor/Tezacaftor/Deutivacaftor Granules
NCT06299696Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Flavor Assessment Based on Flavor Profile Method of Descriptive Sensory Analysis. Started Mar 2024; status: completed.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06299696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299696.